Zevra Therapeutics (ZVRA) Expected to Announce Earnings on Thursday

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) is anticipated to issue its quarterly earnings data before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.39) per share and revenue of $8.93 million for the quarter. Persons that wish to listen to the company's earnings conference call can do so using this link.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last announced its quarterly earnings data on Tuesday, March 11th. The company reported ($0.67) EPS for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.28). The company had revenue of $12.00 million for the quarter, compared to analyst estimates of $8.93 million. Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. On average, analysts expect Zevra Therapeutics to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Zevra Therapeutics Trading Down 0.9 %

Shares of Zevra Therapeutics stock traded down $0.07 during trading on Friday, hitting $7.94. 249,824 shares of the company were exchanged, compared to its average volume of 576,297. The firm has a market capitalization of $429.68 million, a P/E ratio of -4.03 and a beta of 1.98. The firm's fifty day moving average price is $7.90 and its 200 day moving average price is $8.17. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.88 and a quick ratio of 2.88. Zevra Therapeutics has a 1-year low of $4.20 and a 1-year high of $9.76.

Remove Ads

Insider Transactions at Zevra Therapeutics

In other news, CEO Neil F. Mcfarlane sold 61,273 shares of the company's stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $7.86, for a total transaction of $481,605.78. Following the completion of the transaction, the chief executive officer now directly owns 222,060 shares in the company, valued at approximately $1,745,391.60. This represents a 21.63 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO R. Laduane Clifton sold 11,000 shares of the stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $7.86, for a total value of $86,460.00. Following the completion of the transaction, the chief financial officer now owns 51,361 shares of the company's stock, valued at $403,697.46. This represents a 17.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 85,773 shares of company stock valued at $674,176. Corporate insiders own 2.40% of the company's stock.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the company. Guggenheim upped their price objective on Zevra Therapeutics from $20.00 to $22.00 and gave the stock a "buy" rating in a research report on Thursday, March 13th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $25.00 target price on shares of Zevra Therapeutics in a research report on Wednesday, March 12th. HC Wainwright restated a "buy" rating and set a $20.00 price objective on shares of Zevra Therapeutics in a research note on Thursday, March 13th. JMP Securities set a $18.00 price objective on Zevra Therapeutics in a report on Wednesday, March 12th. Finally, Citigroup reiterated an "outperform" rating on shares of Zevra Therapeutics in a report on Wednesday, March 12th. Eight investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $22.29.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.